The Three Possible Reasons MSNBC’s Joe Scarborough Totally Missed Joe Biden’s OBVIOUS Ment...
Dana Perino Buries Biden's 'Farewell Speech' in the Graveyard of Hypocrisy and Gaslighting
Adam Kinzinger Says if Trump 'Abandons' Ukraine it Will Be Worse Than Afghanistan
Claim to Flame: Hunter Biden’s California Wildfire-Consumed Paintings Spark Funny Art Spec...
Joe Biden Warns Us Against the Tech Bros (i.e., Elon Musk) in Farewell...
State Senator: If There Are Freeloaders in the US, It's the Top 1...
Kamala Harris Thanks the Leadership of Joe Biden for the Ceasefire and Hostage...
CBS News Says Insurance Rates Are Skyrocketing Because of Climate Change
CNN's Jake Tapper Introduces Biden's Farewell Address With the 'Since the Civil War'...
Trump’s CIA Director Nominee Calls Out Adam Schiff for the Laptop Story
Backstabbing Besties: Jill Biden Mad Nancy Pelosi Choose Money and Power Over Friendship...
COPE and SEETHE: Antifascist Podcaster Is SO MAD About Pete Hegseth He Wants...
Adam Schiff Begs Pam Bondi to Stop Trump Making Fun of His ‘Watermelon...
CNN Poll: Biden Leaves Office With His Approval Rating at Its Lowest
Phase One of Hostage Release to Include TWO of THREE Cherished American Captives...

Christina Pushaw busts the AP for acknowledging a COVID treatment fact they shamed Ron DeSantis for pointing out just a few months ago

Yesterday, the Associated Press’ Matthew Perrone reported a possible setback for a couple of COVID19 treatments, including Regeneron.

Advertisement

More from the AP:

As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard drugs they’ve used to fight infections are unlikely to work against the new strain.

For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital.

But both drugmakers recently warned that laboratory testing suggests their therapies will be much less potent against omicron, which contains dozens of mutations that make it harder for antibodies to attack the virus. And while the companies say they can quickly develop new omicron-targeting antibodies, those aren’t expected to launch for at least several months.

The fact that Regeneron may not be as effective against the omicron variant as it’s been against others is noteworthy enough. But Gov. Ron DeSantis’ press secretary Christina Pushaw finds something else noteworthy, too:

Things sure have changed, haven’t they? Recall this past August, when the AP was entertaining the idea that DeSantis was promoting sketchy Regeneron in some kind of quid pro quo scheme because one of his top donors had invested money in Regeneron, making DeSantis shady AF and not to be trusted.

Advertisement

Pushaw called out the AP then.

Just like she’s calling out the AP now.

We’ve got whiplash.

And Pushaw’s got one last question for the AP:

Join the conversation as a VIP Member

Recommended

Trending on Twitchy Videos

Advertisement
Advertisement
Advertisement